Skip to main content

Table 1 Baseline characteristics of cohorts 1 and 2

From: Circulating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn’s disease, and clinical prognosis in inflammatory bowel disease

Baseline Characteristics Cohort 1 Cohort 2
Control UC CD Control UC CD
LL-37 Range (ng/mL) 23–79 12–245 13–94 26–70 21–167 13–282
Age at Collection (mean ± SEM) 46 ± 2 40 ± 2 35 ± 2 43 ± 3 37 ± 1 38 ± 2
Age at diagnosis (mean ± SEM)   35 ± 2 30 ± 2   28 ± 1 25 ± 1
Duration of Disease in Years (mean ± SEM)   6 ± 1 6 ± 1   8 ± 1 13 ± 2
Gender (% Male) 42% 35% 25% 40% 56% 52%
Percentage of patients who used biologics   13% 38%   16% 45%
Percentage of patients who used steroids   17% 52%   32% 30%
Percentage of patients who used immunomodulators   9% 14%   21% 38%
Percentage of patients who used 5-aminosalicyclic acid (5-ASA)   74% 24%   58% 24%
Percentage of Current Smoker (%) 20% 13% 21% 20% 7% 12%
C-reactive protein (CRP) Levels (mg/L) (mean ± SEM)   1.18 ± 0.42 4.77 ± 1.43   0.75 ± 0.16 1.59 ± 0.39
UC Partial Mayo Score (mean ± SEM)   2.09 ± 0.47    3.04 ± 0.29  
UC Mayo Endoscopic Score (mean ± SEM)   1.64 ± 0.19    1.13 ± 0.14  
UC Partial Mayo Score 6–18 months later (mean ± SEM)   2.40 ± 0.52    1.59 ± 0.28  
Montreal Classification of UC:
UC ulcerative proctitis E1 (%)   38%    16%  
UC left sided colitis E2 (%)   24%    59%  
UC pancolitis E3 (%)   29%    22%  
CD Harvey Bradshaw Index (mean ± SEM)    3.67 ± 0.77    4.22 ± 0.44
CD Harvey Bradshaw Index 6–18 months later (mean ± SEM)    2.54 ± 0.65    1.38 ± 0.26
Montreal Classification of CD:
CD Age at diagnosis less than 16 years A1 %    12%    27%
CD Age at diagnosis 17–40 years A2 %    59%    60%
CD Age at diagnosis over 40 years A3 %    29%    12%
CD ileal L1 (%)    56%    23%
CD colonic L2 (%)    6%    15%
CD ilealcolonic L3 (%)    38%    63%
CD isolated upper digestive tract L4 (%)    13%    7%
CD non-stricturing, non-penetrating B1 (%)    43%    57%
CD stricturing B2 (%)    50%    24%
CD penetrating B3 (%)    11%    27%
CD perianal disease P (%)    11%    0%
  50 23 28 20 57 67